CPP-109 Clinical Trial Data to be Presented at the American Society of Addiction Medicine Annual Medical-Scientific Conference

April 9, 2010

CORAL GABLES, Fla., April 9, 2010 /PRNewswire-FirstCall/ — Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: “A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence” at the American Society of Addiction Medicine’s (ASAM) 41st Annual Medical-Scientific Conference in San Francisco, CA. Dr. Somoza was the Coordinating Principal Investigator for the trial and will discuss data from Catalyst’s U.S. Phase II trial evaluating CPP-109, Catalyst’s form of vigabatrin, to treat cocaine addiction. Further, the Company reported that the presentation materials from the conference will be posted on April 16th on the Company’s website, www.catalystpharma.com, under “Events and Presentations.”

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. Catalyst has two products in development, and is currently evaluating the lead product candidate, CPP-109 (vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction. CPP-109 has been granted “Fast Track” status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction, which indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address an unmet medical need. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions and obsessive-compulsive disorders. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor that could be more potent than vigabatrin but may have reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including epilepsy and drug addiction. Catalyst believes that it controls all current intellectual property for drugs that have a mechanism of action related to GABA aminotransferase. For more information about the Company, go to www.catalystpharma.com.

SOURCE Catalyst Pharmaceutical Partners, Inc.

Source: newswire

comments powered by Disqus